NCT00386737

Brief Summary

Annually, asthma is responsible for 1 million emergency room visits, 400,000 hospitalizations, and 5000 deaths according to the NHLBI. In addition, 10 million missed school-days per year and 100 million days of restricted activity are attributed to this disease. While there is no known cause or cure for asthma, recent studies have shown that hospitalizations and emergency room visits can be reduced by as much as 78% and 73%, respectively, when the disease is properly managed. According to the EPA, the occurance of children with asthma more than doubled the rate of two decades ago; in 2001 the percentage of asthmatic children was 8.7% (6.3 million children). Properly managing asthma is nontrivial and can often require an asthma specialist. The difficulty in diagnosing and managing asthma lies primarily in the lack of available clinical technologies capable of assessing airway inflammation, an early and persistent component of asthma. Accordingly, the National Institutes of Health (NIH) guidelines for the diagnosis and management of asthma strongly recommend long term anti-inflammatory therapies, such as oral or inhaled corticosteroids, to reverse airway inflammation in an effort to prevent irreversible airway damage, termed "airway remodeling". The medical community has expressed the need for more objective and noninvasive measures of airway inflammation for diagnosing asthma and monitoring the effectiveness and compliance of anti-inflammatory therapies. The clinical research plan is designed to evaluate airway inflammation associated with asthma. In this human subjects study, a non-invasive exhaled breath analysis sensor, called the Breathmeter, will be used to measure eNO concentrations in children and adults (ages 4-65) with a broad range of respiratory disorders as well as those with no known respiratory disorders. Breath donations will be simple and straightforward presenting little to no discomfort to volunteers.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2004

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2004

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

October 11, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 12, 2006

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2007

Completed
Last Updated

October 12, 2006

Status Verified

October 1, 2006

First QC Date

October 11, 2006

Last Update Submit

October 11, 2006

Conditions

Keywords

AsthmaBreath TestingLaser SpectroscopyeNONitric OxideLower Airway InflammationCarbon DioxideCO2

Eligibility Criteria

Age4 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy subjects (n=120)
  • Asthma (Total n=450) \[diagnosed according to NHLBI/ NAEPP Guidelines (1998)\]
  • Non-treated or B2-agonist treated asthmatics (n=150),
  • Glucocorticoid treated asthmatics, (n=150),
  • Leukotriene Antagonist treated asthmatics, (n=75),
  • Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75).
  • Acute respiratory illnesses (n=65
  • Sinusitis (Acute and Chronic),
  • Influenza,
  • Common cold,
  • Pneumonia,
  • Related symptoms, but no diagnosis.
  • Allergies (n=65)
  • Atopic dermatitis,
  • Allergic rhinitis,
  • +1 more criteria

You may not qualify if:

  • Younger than 4
  • Older than 65
  • Pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ekips Technologies, Inc.

Norman, Oklahoma, 73069, United States

RECRUITING

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Khosrow Namjou, Ph.D.

    Ekips Technologies, Inc.

    PRINCIPAL INVESTIGATOR

Central Study Contacts

G. Carl Gibson, BBA

CONTACT

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
OTHER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 11, 2006

First Posted

October 12, 2006

Study Start

September 1, 2004

Study Completion

February 1, 2007

Last Updated

October 12, 2006

Record last verified: 2006-10

Locations